Resveratrol for Alzheimer's disease. Issue 1 (16th August 2017)

• Record Type: Journal Article
• Authors: Sawda, Christine; Moussa, Charbel; Turner, R. Scott
• Other Names: Vanga Ole guestEditor.; Lin Hung‐Yun guestEditor.
• Is Part Of: Annals of the New York Academy of Sciences. Volume 1403:Issue 1(2017)
• Page Start: 142
• Page End: 149
• Publication Date: 2017-08-16
• Subjects: Alzheimer's disease -- resveratrol -- sirtuin -- polyphenol -- amyloid; Medical sciences -- Periodicals; Medicine -- Periodicals; Science -- Periodicals; 610
• DOI: 10.1111/nyas.13431
• Languages: English
• ISSNs: 0077-8923

Abstract

Abstract: The amyloid hypothesis suggests that the progressive accumulation and deposition of central nervous system (CNS) amyloid with aging is the proximate cause of Alzheimer's disease (AD). Thus, targeting molecular mechanisms of aging may be a viable treatment approach. Caloric restriction prevents diseases of aging, including AD, in animal models, perhaps by activation of sirtuins. The sirtuins (e.g., mammalian SIRT1) are deacetylases that link energy balance (NAD + /NADH) to regulation of gene transcription. Resveratrol is a potent activator of SIRT1, and thus may mimic caloric restriction to prevent diseases of aging. We conducted a randomized, double‐blind, placebo‐controlled, phase II trial of resveratrol for individuals with mild‐to‐moderate AD. Resveratrol (1) is detectable in cerebrospinal fluid (at low nanomolar levels), (2) is safe and well tolerated, (3) alters AD biomarker trajectories, (4) preserves blood–brain barrier integrity, and (5) modulates the CNS immune response. Further studies are needed to determine the safety and efficacy of resveratrol and the validity of this approach in the treatment and prevention of AD and other diseases of aging.